Previous Close | 4.8000 |
Open | 4.8300 |
Bid | 4.7500 x 2200 |
Ask | 4.8200 x 2200 |
Day's Range | 4.7000 - 4.8600 |
52 Week Range | 2.5400 - 4.9800 |
Volume | 649,502 |
Avg. Volume | 261,786 |
Market Cap | 582.229M |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | 16.35 |
EPS (TTM) | 0.2930 |
Earnings Date | Feb 25, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jul 31, 2018 |
1y Target Est | N/A |
Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors (the "Board") has received a non-binding proposal letter from Alternate Ocean Investment Company Limited ("Alternate Ocean"), a wholly-owned subsidiary of Haitong International Securities Group Limited (Stock Code: 665.HK), pursuant to which Alternate Ocean, acting on behalf of certain funds and/or entities that it manages and/or advises, proposes to acquire all of the outstanding ordinary shares of the Company for US$5.00 per ordinary share in cash, subject to certain conditions.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Global Cord Blood Corp. (NYSE:CO) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 25, 2021 at 8:00 AM Eastern Time.
Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal 2021, ended December 31, 2020.